Health Care · Pharmaceutical Preparations

KROS Keros Therapeutics, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 1664710106 filings
Russell 2000

KROS at a glance

Keros Therapeutics, Inc. (KROS, SEC CIK 1664710) filed its latest 10-K annual report on March 4, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 16, 2026 and Form 4 insider filings as recently as November 19, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Keros Therapeutics, Inc. (KROS) reported revenue of $244.1 million (up 6775.0% from FY2024) and net income of $87.0 million. Diluted EPS was $2.30.
  • As of September 30, 2026, 24 institutional investment managers tracked by SignalX reported holding Keros Therapeutics, Inc. (KROS) shares worth $103.7 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Newton Charles W. on November 17, 2026 of 491 shares at $10.83 per share.
  • In the last 90 days, KROS insiders reported 0 open-market purchases ($0) and 5 open-market sales ($18K) on Form 4, a net sale of $18K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$244.1M
+6775.0% vs prior year
Insiders · 90 days
0 buys · 5 sells
Net −$18K
13F holders
24 funds
$103.7M · −2 vs prior quarter
Latest 8-K
Nov 16, 2026
Item 8.01

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • Regulatory risk: EU Pharma Package could reduce orphan exclusivity from 10 to 9 years, accelerating generic or biosimilar competition
  • Financial risk: $259.5 million cash and cash equivalents expected to fund operations into the second half of 2028
  • Clinical risk: Cibotercept TROPOS trial terminated after unanticipated pericardial effusion adverse events
  • Competitive risk: DMD competition expanded following Sarepta, Avidity Biosciences and Edgewise Therapeutics developments
  • Compliance risk: UK clinical-trial amendments effective April 28, 2026 may increase CRO compliance costs and delay trial initiation

Management Discussion & Analysis

  • Quarterly revenue $40.0M, up $25.7M YoY from $14.3M, driven by Takeda milestones
  • Net income $14.2M vs $7.3M loss YoY, operating margin 32.0% vs negative 107.9%
  • Rinvatercept R&D $5.0M, up $3.7M YoY, best-performing pipeline line
  • Cash $259.5M; operating cash flow $(20.6)M vs $134.8M YoY
  • Cash runway into second half of 2028; inflation, tariffs and capital-market volatility headwinds

AI summary of the KROS 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 16, 2026Full analysis →

Item 8.01: Other Events

  • $5 million common-stock repurchase program approved after receiving a $20 million Takeda development milestone
  • Cash and equivalents totaled $259.5 million as of September 30, 2026

Item EX-99.1: Item EX-99.1

  • $5 million share repurchase authorization following $20 million elritercept development milestone payment from Takeda
  • Capital return signals management views repurchases as an attractive use of milestone proceeds
Filed Nov 5, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Updated corporate presentation signals refreshed investor messaging and potentially new company or pipeline information
  • Exhibit 99.1 contains the substantive presentation, available through Keros Therapeutics’ website

Item EX-99.1: Item EX-99.1

  • November 2026 presentation highlights rinvatercept’s expanding pipeline role across DMD and ALS, increasing potential value beyond a single indication
  • Phase 2 DMD basket trial commenced, with initial data expected in first half of 2027
Filed Nov 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results and recent business highlights announced for the quarter ended September 30, 2026
  • Exhibit 99.1 contains the detailed results and operational updates relevant to investors

Item EX-99.1: Item EX-99.1

  • Q3 2026 net income $14.2M, or $0.71 basic EPS, versus $7.3M loss, driven by $40.0M license revenue
  • Nine-month net loss $38.3M despite $40.0M license revenue, highlighting continued operating losses without partnering income

AI summaries of KROS 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for KROS

Don't miss the next KROS filing

  • Alerts as it files. A push when KROS files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut KROS, by share count.
  • Ask anything. An AI agent that reads every KROS filing and answers with sources.

KROS alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Newton Charles W.SellNov 17, 2026$10.83
Newton Charles W.SellNov 17, 2026$11.05
Prener AnneSellNov 17, 2026$11.03
Prener AnneSellNov 17, 2026$10.77
Prener AnneSellNov 12, 2026$9.79
Cho EstherSellAug 18, 2026$10.29
Lerner Lorena RaquelSellAug 18, 2026$10.29
Tanini AnnitaSellAug 18, 2026$10.29

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$151K$3.5M$244.1M
Operating Income--$210.8M$67.6M
Net Income-$153.0M-$187.4M$87.0M
Op. Margin--5939.0%27.7%
Net Margin-101319.2%-5277.5%35.7%
Balance Sheet
Total Assets-$615.9M$338.0M
Equity-$571.6M$303.1M
ROE--32.8%28.7%
Per Share
EPS$-5.20$-5.00$2.30
Cash Flow
Operating CF--$160.9M$107.5M
CapEx$2.5M$1.9M$1.6M

Source: XBRL data in Keros Therapeutics, Inc. (KROS)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate KROS share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
KROS shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202624$103.7M
Q2 202626$93.7M
Q1 202627$92.4M
Q4 202524$190.2M
Q3 202525$190.5M
Q2 202526$153.5M
Q1 202521$124.3M
Q4 202416$191.8M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 189 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

KROS filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 19, 2026--
4Nov 19, 2026--
4Nov 16, 2026--
8-KNov 16, 2026Analysis-
8-KNov 5, 2026Analysis-
8-KNov 5, 2026Analysis-
10-QNov 5, 2026Analysis
8-KSep 29, 2026Analysis-
8-KSep 28, 2026Analysis-
8-KSep 8, 2026Analysis-
4Aug 20, 2026--
4Aug 20, 2026--
4Aug 20, 2026--
4Aug 20, 2026--
4Aug 19, 2026--
8-KAug 3, 2026Analysis-
10-QAug 3, 2026Analysis
8-KAug 3, 2026Analysis-
8-KJul 30, 2026Analysis-
8-KJul 22, 2026Analysis-
4Jul 17, 2026--
SC 13GJul 17, 2026-
4Jul 6, 2026--
8-KJun 25, 2026Analysis-
4Jun 17, 2026--

Related Health Care companies

All Health Care →

KROS SEC filings: frequently asked questions

Are KROS insiders buying or selling?

In the last 90 days, Keros Therapeutics, Inc. (KROS) officers, directors and 10% owners reported no open-market purchases and 5 open-market sales worth $17,830 by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold KROS stock?

As of September 30, 2026, the largest Keros Therapeutics, Inc. (KROS) holders among the 13F filers tracked by SignalX were BlackRock ($39.9 million), Vanguard Capital Management LLC ($9.5 million), AQR Capital Management ($9.2 million), Vanguard Portfolio Management LLC ($7.3 million), Two Sigma Investments ($6.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was KROS's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Keros Therapeutics, Inc. (KROS) reported revenue of $244.1 million (up 6775.0% from FY2024) and net income of $87.0 million. Diluted EPS was $2.30. The figures come from the XBRL data in the 10-K.

What did KROS report in its latest 8-K?

Keros Therapeutics, Inc. (KROS) filed an 8-K on November 16, 2026 reporting Item 8.01 (Other Events). $5 million common-stock repurchase program approved after receiving a $20 million Takeda development milestone.

What are the latest KROS SEC filings?

Keros Therapeutics, Inc. (KROS) filed its latest 10-K annual report on March 4, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 16, 2026 and a Form 4 insider filing on November 19, 2026.

What is KROS's SEC CIK number?

Keros Therapeutics, Inc. (KROS)'s SEC Central Index Key (CIK) is 1664710. EDGAR lists every KROS filing under that number.

Ask anything about KROS

The research agent reads KROS's filings, financials, insider trades and 13F holders, then answers with sources.